Duopharma Biotech (Malaysia) Investor Sentiment

7148 Stock   1.24  0.01  0.80%   
About 62% of Duopharma Biotech's investor base is looking to short. The analysis of current outlook of investing in Duopharma Biotech Bhd suggests that many traders are alarmed regarding Duopharma Biotech's prospects. Duopharma Biotech's investing sentiment shows overall attitude of investors towards Duopharma Biotech Bhd.
Duopharma Biotech stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Duopharma daily returns and investor perception about the current price of Duopharma Biotech Bhd as well as its diversification or hedging effects on your existing portfolios.
  
over a month ago at news.google.com         
Stock Picks Of The Day Petron Malaysia Duopharma Biotech - BusinessToday
Google News at Macroaxis
over a month ago at news.google.com         
Optimism for Duopharma Biotech Berhad has grown this past week, despite five-year decline in earning...
Google News at Macroaxis
over three months ago at news.google.com         
Duopharma Biotech 2Q net profit up 33, pays one sen dividend - The Edge Markets MY
Google News at Macroaxis
over three months ago at news.google.com         
M3Tech, BIG, Bintai, Duopharma, Grand-Flo, HWGB, LebTech, Pharmaniaga, Rev Asia, Solution, WMG - The...
Google News at Macroaxis
over three months ago at news.google.com         
An Intrinsic Calculation For Duopharma Biotech Berhad Suggests Its 22 percent Undervalued - Yahoo Fi...
Google News at Macroaxis
over three months ago at news.google.com         
Duopharma Biotech brings Flavettes Glow to Indonesia - Markets Insider
Google News at Macroaxis
over six months ago at news.google.com         
Duopharma Biotech Berhad investors are sitting on a loss of 42 percent if they invested three years ...
Google News at Macroaxis
over six months ago at news.google.com         
Duopharma Biotech surges over 9 percent after RM578m contract news - The Edge Malaysia
Google News at Macroaxis
over six months ago at news.google.com         
Duopharma Biotech surges over 9 percent after RM578m contract news - The Edge Malaysia
Google News at Macroaxis
over six months ago at news.google.com         
Duopharma Biotech Berhad Full Year 2023 Earnings Revenues Beat Expectations, EPS Lags - Yahoo Financ...
Google News at Macroaxis
over six months ago at news.google.com         
While individual investors own 28 percent of Duopharma Biotech Berhad , sovereign wealth funds are i...
Google News at Macroaxis
over six months ago at news.google.com         
Are Duopharma Biotech Berhads Fundamentals Good Enough to Warrant Buying Given The ... - Yahoo Finan...
Google News at Macroaxis
over six months ago at news.google.com         
Dupharma Biotech forms RD partnerships for new therapies - Markets Insider
Google News at Macroaxis
over six months ago at news.google.com         
Duopharma Biotech Berhad Pays A RM00.018 Dividend In Just Three Days - Yahoo Finance
Google News at Macroaxis
over six months ago at news.google.com         
Duopharma Biotech partners Owen Mumford to distribute medical devices - Markets Insider
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Duopharma Biotech that are available to investors today. That information is available publicly through Duopharma media outlets and privately through word of mouth or via Duopharma internal channels. However, regardless of the origin, that massive amount of Duopharma data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Duopharma Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Duopharma Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Duopharma Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Duopharma Biotech alpha.

Duopharma Biotech Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Other Information on Investing in Duopharma Stock

Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.